Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776833 | 1.00 | PPARA (0.55) | PPARASYKPPARGCTSKFOLH1 | |
| SCHEMBL5971174 | 1.00 | PPARA (0.55) | PPARASYKPPARGCTSKFOLH1 | |
| SCHEMBL7821853 | 0.93 | FOLH1 (0.54) | PPARASYKPPARGFOLH1SIRT2 | |
| SCHEMBL8113270 | 0.93 | SIRT2 (0.55) | PPARASYKPPARGCTSKFOLH1 | |
| SCHEMBL13570899 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL29336406 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL29336412 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL13570900 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL9819558 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL5972669 | 0.92 | MME (0.55) | PPARASYKCTSKFOLH1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4725553-A2 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4699660-A2 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | CELGENE CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-12503696-B2 | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-12-11 | — | — | US | disclosed |
| EP-4648799-A1 | LIGAND-DRUG CONJUGATES | Sun Pharma Advanced Research Company Ltd (IN) | 2025-11-19 | — | — | EP | disclosed |
| US-5317021-A | Analgesics, anticonvulsants | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-05-31 | — | — | US | disclosed |
| WO-1993020047-A1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993012074-A1 | PEPTIDE MIMETIC COMPOUNDS USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-06-24 | — | — | WO | disclosed |
| US-5202340-A | Analgesics, anticonvulsants, anxiolytic agents, inhibitors for enkephalinases | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0509643-A1 | Anti-cancer compounds | BTG INTERNATIONAL LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| US-5017589-A | Analgesic, antianxiety, anticonvulsant | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0341081-A2 | Novel amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-11-08 | — | — | EP | disclosed |
| US-RE30473-E | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4105852-A | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | MAN2B1, GBA1, SSTR1 | PPARA 3663/4885SYK 1808/4885PPARG 3236/4885 |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | IKZF1, IKZF3, IKZF2 | PPARA 4241/4885SYK 2076/4885PPARG 3909/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | PPARA 3141/4885SYK 3536/4885PPARG 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.